2019 ACR/ARP Annual Meeting*

Results of this pooled analysis of 3 randomized, controlled phase III trials show filgotinib to be well tolerated, with no new safety signals, and low rates of MACE/VTE.

Retrospective cohort suggests HCQ did not protect against MACE among patients initiating treatment within the prior year but did reduce risk of all-cause mortality.

Meta-analysis of 33 randomized, placebo-controlled trials identified no increased short-term risks for MACE or VTE.

Similar disease flare rates with both tapering schedules, but tapering csDMARD first associated with numerically higher DMARD-free remission.

PF-06650833 associated with improvements in SDAI in primary analysis.

Mode of action appears to be in normalization of key downstream pathways of the pathobiology of RA, including lymphocyte and myeloid cell pathways.

Analysis of pooled data from 5 phase III RCTs in RA patients suggests that upadacitinib causes no apparent increase in MACE or VTE over 24 months.

Baricitinib safety through 7 years acceptable and similar to that previously reported.

Positive data from this small 14-patient study support broader investigation of vagus nerve stimulation as a novel therapeutic modality in patients with RA in whom biologics or targeted oral therapies have failed.

Noninferiority of ultralow-dose rituximab for the treatment of RA could not be established by this protocol